Assertio Therapeutics ASRT will be releasing its next round of earnings this Friday, August 07. For all of the relevant information, here is your guide for Friday's Q2 earnings announcement.
Earnings and Revenue
Wall Street expects an EPS loss $-0.03 and sales around $25.33 million. In the same quarter last year, Assertio Therapeutics reported earnings per share of $0.25 on sales of $57.20 million. The Wall Street estimate would represent a 112.0% decline in the company's earnings. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.08 | 0.14 | 0.24 | 0.24 |
| EPS Actual | 0.10 | -0.14 | 0.24 | 0.25 |
| Revenue Estimate | 11.30 M | 50.30 M | 60.74 M | 59.05 M |
| Revenue Actual | 20.92 M | 59.23 M | 55.15 M | 57.20 M |
Stock Performance
Over the last 52-week period, shares are down 38.04%. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Assertio Therapeutics is scheduled to hold the call at 08:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/onwswjoj
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
